See veebileht kasutab küpsiseid kasutaja sessiooni andmete hoidmiseks. Veebilehe kasutamisega nõustute ETISe kasutustingimustega. Loe rohkem
Olen nõus

Kersti Oselin

https://www.etis.ee/CV/Kersti_Oselin/est
kersti.oselin@ut.ee

Teenistuskäik

Töökohad ja ametid
28.09.2015–...   
North Estonian Medical Centre, onkoloog (keemiaraviarst) (0,90)
2003 - 2004 AS EGeen farmakogeneetiliste uuringute projektijuht
2002 - 2003 TÜ farmakoloogia instituut assistent
2000 - 2002 Humboldti Ülikool Charité Kliinik kliinilis farmakoloogia instituut teadur
1999 - 2000 TÜ farmakoloogia instituut assistent
01.09.2012–31.08.2015   
Tartu Ülikool, Arstiteaduskond, Anestesioloogia ja intensiivravi kliinik, anestesioloogia ja intensiivravi teadur (0,25)
2012–01.09.2015   
SA Tartu Ülikooli Kliinikum, Teadur (0,25)
01.09.2011–31.08.2015   
SA Tartu Ülikooli Kliinikum, arst-resident onkoloogias (1,00)
01.09.2007–01.09.2007   
Tartu Ülikool, Arstiteaduskond, Farmakoloogia instituut, farmakoloogia vanemteadur (1,00)
01.02.2007–31.08.2007   
Tartu Ülikool, Arstiteaduskond, Farmakoloogia instituut, erakorraline vanemteadur (1,00)
2007–30.04.2007   
Tartu Ülikool, Arstiteaduskond, Farmakoloogia instituut, Farmakoloogia ja toksikoloogia õppetool, farmakoloogia vanemteadur (1,00)
01.01.2007–31.12.2011   
Suurbritannia Ravimiamet, kliiniline hindaja
2006–2007   
Tartu Ülikool, Arstiteaduskond, Farmakoloogia instituut, erakorraline vanemteadur (1,00)
01.09.2004–31.01.2007   
Tartu Ülikool, Arstiteaduskond, Farmakoloogia instituut, farmakoloogia teadur (1,00)
 
 
Haridustee
1998 - 2003 TÜ arstiteaduskond kliiniline farmakoloogia doktorantuur
1997 - 1998 SA TÜ Kliinikum internatuur
1991 - 1997 TÜ arstiteaduskond ravi eriala
01.09.2011–31.08.2015   
Arstiteaduse residentuur onkoloogia erialal
 
 
Teadusorganisatsiooniline ja -administratiivne tegevus
2016−...   
American Society of Clinical Oncology, liige
2015−...   
European Society of Medical Oncology, liige
2015−...   
EORTC Lung Cancer Group
2009−...   
Eesti Farmakoloogia Selts, liige
1999−...   
Eesti Onkoteraapia Ühing, juhatuse liige
 
 
Loometöö
PK, PD, kliiniliste uuringute disain, onkoloogia
 
 
Lisainfo
NA

Kvalifikatsioon

Teaduskraadid
Kersti Oselin, doktorikraad, 2003, (juh) Lembit Rägo; Rein Pähkla, Studies on the human MDR1, MRP1 and MRP2 ABC transporters: Functional relevance of the genetic polymorphism in the MDR1 and MRP1 gene (MDR1, MRP1 ja MRP2 ABC transporterid: geneetilise polümorfismi tähtsus MDR1 ja MRP1 geenides), Tartu Ülikool, Arstiteaduskond.
 
 
Teadustöö põhisuunad
ETIS KLASSIFIKAATOR: 3. Terviseuuringud; 3.7. Kliiniline meditsiin; TÄPSUSTUS: Kliiniline farmakoloogia, farmakokineetika, farmakogeneetika
ETIS KLASSIFIKAATOR: 3. Terviseuuringud; 3.7. Kliiniline meditsiin; CERCS KLASSIFIKAATOR: B200 Tsütoloogia, onkoloogia, kantseroloogia; TÄPSUSTUS: Infektsioonide nõrgestatud organisms, farmaokineetilised ja farmakogeneetilised uuringud onkoloogiliste ravimitega
ETIS KLASSIFIKAATOR: 3. Terviseuuringud; 3.7. Kliiniline meditsiin; CERCS KLASSIFIKAATOR: B726 Kliiniline bioloogia ; TÄPSUSTUS: onkoloogia, kartsinogenees
 
 
Lisainfo
meditsiinidoktor
Tartu Ülikool, 2003

Lõppenud projektid

Juhendatud väitekirjad

Publikatsioonid

Klass
Aasta
Publikatsioon
 
1.1.
2019
Oselin, Kersti; Girard, Nicolas; Lepik, Karlin; Adamson-Raieste, Aidi; Vanakesa, Tõnu; Almre, Ingemar; Leismann, Tiina; Chalabreysse, Lara (2019). Pathological discrepancies in the diagnosis of thymic epithelial tumors: the Tallinn-Lyon experience. Journal of Thoracic Disease, 11 (2), 456−464.10.21037/jtd.2018.12.123.
1.1.
2018
Padari, Helgi; Metsvaht, Tuuli; Germovsek, Eva; Barker, Charlotte; Kipper, Karin; Herodes, Koit; Standing, Joseph; Oselin, Kersti; Tasa, Tõnis; Soeorg, Hiie; Lutsar, Irja (2018). Pharmacokinetics of penicillin G in preterm and term neonates. Antimicrobial Agents and Chemotherapy.10.1128/AAC.02238-17.
5.2.
2017
Tamm, Madli; Oselin, Kersti; Kivistik, Paula Ann; Kals, Mart; Lokk, Kaie; Keerma, Katrin; Saare, Margot; Roosipuu, Retlav; Leismann, Tiina; Roomere, Hanno; Metspalu, Andres; Tõnisson, Neeme (2017). Monitoring cancer related mutations in cell-free DNA of lung cancer patients. European Journal of Human Genetics: European Human Genetics Conference, Copenhagen, Denmark, May 27–30, 2017. Nature Publishing Group,.
1.1.
2016
Tamme, K.; Oselin, K.; Kipper, K.; Tasa, T.; Metsvaht, T.; Karjagin, J; Herodes, K.; Kern, H.; Starkopf J. (2016). Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam during high volume haemodiafiltration in patients with septic shock. Acta Anaesthesiologica Scandinavica, 60 (2), 230−240.10.1111/aas.12629.
1.1.
2016
Padari, Helgi; Oselin, Kersti; Tasa, Tõnis; Metsvaht, Tuuli; Lõivukene, Krista; Lutsar, Irja (2016). Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target? BMC Pediatrics, 16 (1), 206−206.10.1186/s12887-016-0753-0.
5.2.
2016
Tamm, Madli; Oselin, Kersti; Kivistik, Paula Ann; Keerma, Katrin; Roosipuu, Retlav; Saare, Margot; Roomere, Hanno; Metspalu, Andres; Tõnisson, Neeme (2016). Detecting EGFR and related mutations in the cfDNA of lung cancer patients. European Journal of Human Genetics, 24: European Human Genetics Conference, Barcelona, Spain May 21-24, 2016. Nature Publishing Group, 313−313. (Supplement 1).
1.1.
2012
Padari, H.; Metsvaht, T.; Kõrgvee, LT.; Germovsek, E.; Ilmoja, ML.; Kipper, K.; Herodes, K.; Standing, JF.; Oselin, K.; Lutsar, I. (2012). Short versus Long Infusion of Meropenem in Very-Low-Birth-Weight Neonates. Antimicrobial Agents and Chemotherapy, 56 (9), 4760−4764.10.1128/AAC.00655-12.
1.1.
2011
Heidmets, LT.; Metsvaht, T.; Ilmoja, ML.; Pisarev, H.; Oselin, K.; Lutsar, I. (2011). Blood Loss Related to Participation in Pharmacokinetic Study in Preterm Neonates. Neonatology, 100 (2), 111−115.
1.1.
2008
Tamm, R.; Oselin, K.; Kallassalu, K.; Magi, R.; Anier, K.; Remm, M.; Metspalu, A. (2008). Thiopurine S-methyltransferase (TPMT) pharmacogenetics: three new mutations and haplotype analysis in the Estonian population. Clinical Chemistry and Laboratory Medicine (CCLM), 46 (7), 974−979.
1.1.
2008
Karjagin, J.; Lefeuvre, S.; Oselin, K.; Kipper, K.; Marchand, S.; Tikkerberi, A.; Starkopf, J.; Couet, W.; Sawchuk, R.J. (2008). Pharmacokinetics of Meropenem Determined by Microdialysis in the Peritoneal Fluid of Patients With Severe Peritonitis Associated With Septic Shock. Clinical Pharmacology & Therapeutics, 83 (3), 452−459. DOI: 10.1038/sj.clpt.6100312.
1.1.
2007
Metsvaht, T.; Oselin, K.; Ilmoja, M.; Anier, K.; Lutsar, I. (2007). Pharmacokinetics of penicillin G in very-low-birth-weight neonates. Antimicrobial Agents and Chemotherapy, 51 (6), 1995−2000.
1.1.
2007
Oselin, K.; Anier, K. (2007). Inhibition of human thiopurine S-methyltransferase by various nonsteroidal anti-inflammatory drugs in vitro: a mechanism for possible drug interactions. Drug Metabolism and Disposition, 35 (9), 1452−1454.
3.3.
2007
Brilene, T.; Hedman, A.; Kirss, A.; Kullamaa, A.; Kõrv, J.; Oselin, K.; Otter, K.; Ristimäe, T.; Visnapuu, P.; Peet, K. (2007). Rasedate farmakoteraapia. Tallinn: Medicina.
1.1.
2006
Oselin, K.; Anier, K.; Tamm, R.; Kallassalu, K.; Mäeorg, U. (2006). Determination of thiopurine S-methyltransferase (TPMT) activity by comparing various normalization factors: Reference values for Estonian population using HPLC-UV assay. Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences, 77−83. DOI: 10.1016/j.jchromb.2006.02.031.
5.1.
2006
Metsvaht, T.; Ilmoja, ML.; Oselin, K.; Anier, K.; Lutsar, I. (2006). Pharmacokinetics of penicillin G(Pen) 'steady-state' in very low birth weight premature newborns. BIOLOGY OF THE NEONATE, 90. 281−281.
5.2.
2006
Karjagin, J.; Oselin, K.; Lefeuvre, S.; Tikkerberi, A.; Saar, M.; Paju, T.; Marchand, S.; Couet, W.; Starkopf, J. (2006). Intraperitoneal concentration of meropenem reaches sufficient level in patients with peritonitis. Intensive Care Medicine, 1. 132.
5.2.
2006
Karjagin, J.; Oselin, K.; Lefeuvre, S.; Tikkerberi, A.; Saar, M.; Paju, T.; Marchand, S.; Couet, W.; Starkopf, J. (2006). Intraperitoneal concentration of meropenem reaches sufficient level in patients with peritonitis. Proceedings of 2nd International Baltic Congress of Anaesthesiology and Intensive Care: 2nd International Baltic Congress of Anaesthesiology and Intensive Care; Tallinn, Estonia; 26-28 October 2006. Tallinn, 127.
1.1.
2003
Oselin, K.; Nowakowski-Gashaw, I.; Mrozikiewicz, PM.; Wolbergs, D.; Pahkla, R.; Roots, I. (2003). Quantitative determination of MDR1 mRNA expression in peripheral blood lymphocytes: a possible role of genetic polymorphisms in the MDR1 gene. European Journal of Clinical Investigation, 33 (3), 261−267.
1.1.
2003
Oselin, K.; Mrozikiewicz, PM.; Pahkla, R.; Roots, I. (2003). Quantitative determination of the human MRP1 and MRP2 mRNA expression in FACS-sorted peripheral blood CD4(+), CD8(+), CD19(+), and CD56(+) cells. European Journal of Haematology, 71 (2), 119−123.
1.1.
2003
Oselin, K.; Mrozikiewicz, PM.; Gaikovitch, E.; Pahkla, R.; Roots, I. (2003). Frequency of MRP1 genetic polymorphisms and their functional significance in Caucasians: detection of a novel mutation G816A in the human MRP1 gene. European Journal of Clinical Pharmacology, 59 (4), 347−350.
1.1.
2003
Oselin, K.; Gerloff, T.; Mrozikiewicz, PM.; Pahkla, R.; Roots, I. (2003). MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fundamental & Clinical Pharmacology, 17 (4), 463−469.
1.1.
2003
Kalev, I.; Osolin, K.; Pärlist, P.; Zilmer, M.; Rajasalu, T.; Podar, T.; Mikelsaar, AV. (2003). CC-chemokine receptor CCR5-del32 mutation as a modifying pathogenetic factor in type I diabetes. Journal of Diabetes and its Complications, 17 (6), 387−391.
6.6.
2003
Oselin, K. (2003). Iivelduse ja oksendamise farmakoloogiline ravi. Lege Artis, 2(16), 49−52.
1.1.
2002
Gerloff, T.; Schaefer, M.; Johne, A.; Oselin, K.; Meisel, C.; Cascorbi, I.; Roots, I. (2002). MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. British Journal of Clinical Pharmacology, 54 (6), 610−616.
1.3.
2002
Kalev, I.; Podar, T.; Oselin, K.; Pärlist, P.; Tasa, G.; Mikelsaar, A. (2002). Kemokiiniretseptori CCR5 geeni polümorfism eestlastel ja mutatsiooni ccr5-delta-32 seos diabeediga. Eesti Arst, 2, 62−69.
1.2.
2001
Kalev, I.; Oselin, K.; Pärlist, P.; Podar, T.; Mikelsaar, A. (2001). CC-chemokine receptor CCR5 gene polymorphism analysis in diabetes Type I and Type II patients in Estonia. European Journal of Human Genetics, 9 (269), 269.
1.1.
1999
Pahkla, R.; Irs, A.; Oselin, K.; Rootslane, L. (1999). Digoxin: use pattern in Estonia and bioavailability of the local market leader. Journal of Clinical Pharmacy and Therapeutics, 24 (5), 375−380.
11.07.2019

Kersti Oselin

https://www.etis.ee/CV/Kersti_Oselin/eng
kersti.oselin@ut.ee

Career

Institutions and positions
28.09.2015–...   
North Estonian Medical Centre, medical oncologist (0,90)
2003 - 2004 EGeen International Corporation, project manager of pharmacogenetic studies
2002 - 2003 Institute of Pharmacolgy, University of Tartu, assistent
2000 - 2002 University of Humboldt, Charité Clinics, Institute of Clinical Pharmacology, researcher
1999 - 2000 Institute of Pharmacolgy, University of Tartu, assistent
01.09.2012–31.08.2015   
University of Tartu, Faculty of Medicine, Department of Anesthesiology and Intensive Care, Research Fellow in Anesthesiology and Intensive Care (0,25)
2012–01.09.2015   
Tartu University Hospital, Researcher (0,25)
01.09.2011–31.08.2015   
Tartu University Hospital, specialist registrar in oncology (1,00)
01.09.2007–01.09.2007   
University of Tartu, Faculty of Medicine, Department of Pharmacology, Senior Research Fellow (1,00)
01.02.2007–31.08.2007   
University of Tartu, Faculty of Medicine, Department of Pharmacology, Senior Research Fellow extraordinarius (1,00)
2007–30.04.2007   
University of Tartu, Faculty of Medicine, Department of Pharmacology, Chair of Pharmacology and Toxicology, farmakoloogia vanemteadur (1,00)
01.01.2007–31.12.2011   
Medicines and Healthcare Products Regulatory Agency, clinical assessor
2006–2007   
University of Tartu, Faculty of Medicine, Department of Pharmacology, erakorraline vanemteadur (1,00)
01.09.2004–31.01.2007   
University of Tartu, Faculty of Medicine, Department of Pharmacology, Research Fellow (1,00)
 
 
Education
1998 - 2003 PhD-studies in clinical pharmacology, University of Tartu
1997 - 1998 Internship, Tartu University Clinics
1991 - 1997 Medical Faculty, University of Tartu.
01.09.2011–31.08.2015   
Specialist medical training in oncology
 
 
R&D related managerial and administrative work
2016−...   
American Society of Clinical Oncology, member
2015−...   
European Society of Medical Oncology, member
2015−...   
EORTC Lung Cancer Group
2009−...   
Estonian Society of Farmocology, member
1999−...   
Estonian Society of Medical Oncology, member of board
 
 
Creative work
PK, PD clinical trial design, medical oncology

Qualifications

Academic degrees
Kersti Oselin, Doctor's Degree, 2003, (sup) Lembit Rägo; Rein Pähkla, Studies on the human MDR1, MRP1 and MRP2 ABC transporters: Functional relevance of the genetic polymorphism in the MDR1 and MRP1 gene, University of Tartu, Faculty of Medicine.
 
 
Fields of research
ETIS CLASSIFICATION: 3. Health; 3.7. Clinical Medicine; SPECIFICATION: Clinical pharmacology, pharmacokinetics, pharmacogenomics
ETIS CLASSIFICATION: 3. Health; 3.7. Clinical Medicine; CERCS CLASSIFICATION: B200 Cytology, oncology, cancerology; SPECIFICATION: Infections of the immunsupressed host, pharmacokinetics and pharmacogenetics of medical oncology
ETIS CLASSIFICATION: 3. Health; 3.7. Clinical Medicine; CERCS CLASSIFICATION: B726 Clinical biology ; SPECIFICATION: oncology, carcinogenesis
 
 
Additional information
Ph.D.
University of Tartu, 1998

Completed projects

Supervised dissertations

Publications

Category
Year
Publication
 
1.1.
2019
Oselin, Kersti; Girard, Nicolas; Lepik, Karlin; Adamson-Raieste, Aidi; Vanakesa, Tõnu; Almre, Ingemar; Leismann, Tiina; Chalabreysse, Lara (2019). Pathological discrepancies in the diagnosis of thymic epithelial tumors: the Tallinn-Lyon experience. Journal of Thoracic Disease, 11 (2), 456−464.10.21037/jtd.2018.12.123.
1.1.
2018
Padari, Helgi; Metsvaht, Tuuli; Germovsek, Eva; Barker, Charlotte; Kipper, Karin; Herodes, Koit; Standing, Joseph; Oselin, Kersti; Tasa, Tõnis; Soeorg, Hiie; Lutsar, Irja (2018). Pharmacokinetics of penicillin G in preterm and term neonates. Antimicrobial Agents and Chemotherapy.10.1128/AAC.02238-17.
5.2.
2017
Tamm, Madli; Oselin, Kersti; Kivistik, Paula Ann; Kals, Mart; Lokk, Kaie; Keerma, Katrin; Saare, Margot; Roosipuu, Retlav; Leismann, Tiina; Roomere, Hanno; Metspalu, Andres; Tõnisson, Neeme (2017). Monitoring cancer related mutations in cell-free DNA of lung cancer patients. European Journal of Human Genetics: European Human Genetics Conference, Copenhagen, Denmark, May 27–30, 2017. Nature Publishing Group,.
1.1.
2016
Tamme, K.; Oselin, K.; Kipper, K.; Tasa, T.; Metsvaht, T.; Karjagin, J; Herodes, K.; Kern, H.; Starkopf J. (2016). Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam during high volume haemodiafiltration in patients with septic shock. Acta Anaesthesiologica Scandinavica, 60 (2), 230−240.10.1111/aas.12629.
1.1.
2016
Padari, Helgi; Oselin, Kersti; Tasa, Tõnis; Metsvaht, Tuuli; Lõivukene, Krista; Lutsar, Irja (2016). Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target? BMC Pediatrics, 16 (1), 206−206.10.1186/s12887-016-0753-0.
5.2.
2016
Tamm, Madli; Oselin, Kersti; Kivistik, Paula Ann; Keerma, Katrin; Roosipuu, Retlav; Saare, Margot; Roomere, Hanno; Metspalu, Andres; Tõnisson, Neeme (2016). Detecting EGFR and related mutations in the cfDNA of lung cancer patients. European Journal of Human Genetics, 24: European Human Genetics Conference, Barcelona, Spain May 21-24, 2016. Nature Publishing Group, 313−313. (Supplement 1).
1.1.
2012
Padari, H.; Metsvaht, T.; Kõrgvee, LT.; Germovsek, E.; Ilmoja, ML.; Kipper, K.; Herodes, K.; Standing, JF.; Oselin, K.; Lutsar, I. (2012). Short versus Long Infusion of Meropenem in Very-Low-Birth-Weight Neonates. Antimicrobial Agents and Chemotherapy, 56 (9), 4760−4764.10.1128/AAC.00655-12.
1.1.
2011
Heidmets, LT.; Metsvaht, T.; Ilmoja, ML.; Pisarev, H.; Oselin, K.; Lutsar, I. (2011). Blood Loss Related to Participation in Pharmacokinetic Study in Preterm Neonates. Neonatology, 100 (2), 111−115.
1.1.
2008
Tamm, R.; Oselin, K.; Kallassalu, K.; Magi, R.; Anier, K.; Remm, M.; Metspalu, A. (2008). Thiopurine S-methyltransferase (TPMT) pharmacogenetics: three new mutations and haplotype analysis in the Estonian population. Clinical Chemistry and Laboratory Medicine (CCLM), 46 (7), 974−979.
1.1.
2008
Karjagin, J.; Lefeuvre, S.; Oselin, K.; Kipper, K.; Marchand, S.; Tikkerberi, A.; Starkopf, J.; Couet, W.; Sawchuk, R.J. (2008). Pharmacokinetics of Meropenem Determined by Microdialysis in the Peritoneal Fluid of Patients With Severe Peritonitis Associated With Septic Shock. Clinical Pharmacology & Therapeutics, 83 (3), 452−459. DOI: 10.1038/sj.clpt.6100312.
1.1.
2007
Metsvaht, T.; Oselin, K.; Ilmoja, M.; Anier, K.; Lutsar, I. (2007). Pharmacokinetics of penicillin G in very-low-birth-weight neonates. Antimicrobial Agents and Chemotherapy, 51 (6), 1995−2000.
1.1.
2007
Oselin, K.; Anier, K. (2007). Inhibition of human thiopurine S-methyltransferase by various nonsteroidal anti-inflammatory drugs in vitro: a mechanism for possible drug interactions. Drug Metabolism and Disposition, 35 (9), 1452−1454.
3.3.
2007
Brilene, T.; Hedman, A.; Kirss, A.; Kullamaa, A.; Kõrv, J.; Oselin, K.; Otter, K.; Ristimäe, T.; Visnapuu, P.; Peet, K. (2007). Rasedate farmakoteraapia. Tallinn: Medicina.
1.1.
2006
Oselin, K.; Anier, K.; Tamm, R.; Kallassalu, K.; Mäeorg, U. (2006). Determination of thiopurine S-methyltransferase (TPMT) activity by comparing various normalization factors: Reference values for Estonian population using HPLC-UV assay. Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences, 77−83. DOI: 10.1016/j.jchromb.2006.02.031.
5.1.
2006
Metsvaht, T.; Ilmoja, ML.; Oselin, K.; Anier, K.; Lutsar, I. (2006). Pharmacokinetics of penicillin G(Pen) 'steady-state' in very low birth weight premature newborns. BIOLOGY OF THE NEONATE, 90. 281−281.
5.2.
2006
Karjagin, J.; Oselin, K.; Lefeuvre, S.; Tikkerberi, A.; Saar, M.; Paju, T.; Marchand, S.; Couet, W.; Starkopf, J. (2006). Intraperitoneal concentration of meropenem reaches sufficient level in patients with peritonitis. Intensive Care Medicine, 1. 132.
5.2.
2006
Karjagin, J.; Oselin, K.; Lefeuvre, S.; Tikkerberi, A.; Saar, M.; Paju, T.; Marchand, S.; Couet, W.; Starkopf, J. (2006). Intraperitoneal concentration of meropenem reaches sufficient level in patients with peritonitis. Proceedings of 2nd International Baltic Congress of Anaesthesiology and Intensive Care: 2nd International Baltic Congress of Anaesthesiology and Intensive Care; Tallinn, Estonia; 26-28 October 2006. Tallinn, 127.
1.1.
2003
Oselin, K.; Nowakowski-Gashaw, I.; Mrozikiewicz, PM.; Wolbergs, D.; Pahkla, R.; Roots, I. (2003). Quantitative determination of MDR1 mRNA expression in peripheral blood lymphocytes: a possible role of genetic polymorphisms in the MDR1 gene. European Journal of Clinical Investigation, 33 (3), 261−267.
1.1.
2003
Oselin, K.; Mrozikiewicz, PM.; Pahkla, R.; Roots, I. (2003). Quantitative determination of the human MRP1 and MRP2 mRNA expression in FACS-sorted peripheral blood CD4(+), CD8(+), CD19(+), and CD56(+) cells. European Journal of Haematology, 71 (2), 119−123.
1.1.
2003
Oselin, K.; Mrozikiewicz, PM.; Gaikovitch, E.; Pahkla, R.; Roots, I. (2003). Frequency of MRP1 genetic polymorphisms and their functional significance in Caucasians: detection of a novel mutation G816A in the human MRP1 gene. European Journal of Clinical Pharmacology, 59 (4), 347−350.
1.1.
2003
Oselin, K.; Gerloff, T.; Mrozikiewicz, PM.; Pahkla, R.; Roots, I. (2003). MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fundamental & Clinical Pharmacology, 17 (4), 463−469.
1.1.
2003
Kalev, I.; Osolin, K.; Pärlist, P.; Zilmer, M.; Rajasalu, T.; Podar, T.; Mikelsaar, AV. (2003). CC-chemokine receptor CCR5-del32 mutation as a modifying pathogenetic factor in type I diabetes. Journal of Diabetes and its Complications, 17 (6), 387−391.
6.6.
2003
Oselin, K. (2003). Iivelduse ja oksendamise farmakoloogiline ravi. Lege Artis, 2(16), 49−52.
1.1.
2002
Gerloff, T.; Schaefer, M.; Johne, A.; Oselin, K.; Meisel, C.; Cascorbi, I.; Roots, I. (2002). MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. British Journal of Clinical Pharmacology, 54 (6), 610−616.
1.3.
2002
Kalev, I.; Podar, T.; Oselin, K.; Pärlist, P.; Tasa, G.; Mikelsaar, A. (2002). Kemokiiniretseptori CCR5 geeni polümorfism eestlastel ja mutatsiooni ccr5-delta-32 seos diabeediga. Eesti Arst, 2, 62−69.
1.2.
2001
Kalev, I.; Oselin, K.; Pärlist, P.; Podar, T.; Mikelsaar, A. (2001). CC-chemokine receptor CCR5 gene polymorphism analysis in diabetes Type I and Type II patients in Estonia. European Journal of Human Genetics, 9 (269), 269.
1.1.
1999
Pahkla, R.; Irs, A.; Oselin, K.; Rootslane, L. (1999). Digoxin: use pattern in Estonia and bioavailability of the local market leader. Journal of Clinical Pharmacy and Therapeutics, 24 (5), 375−380.
11.07.2019

Otsi projekti

  • {{item.Name}}
Asutus on projekti finantseerija   Asutus on projekti teostaja  
  • {{searchListItem.Name}}
Kõik   Tavaprojektid   Ülemprojektid   Alamprojektid  
Uus Frascati (2015)
Uus ja vana Frascati (otsing uue järgi väljastab ka seotud vanad)
Kõik
Käimasolevad
Lõppenud
Algus
Hajus
Täpne
Lihtotsing Tühjenda
  • Leitud 9 kirjet
ProgrammLiikNumberNimiProjekti algusProjekti lõppVastutav täitjaAsutusFinantseerijapoolne rahastamine
SFSF0182135As02Afektiivsete häirete ja neurodegeneratiivsete haiguste farmakoteraapia alused01.01.200231.12.2006Aleksandr ŽarkovskiTartu Ülikool, Arstiteaduskond360 589,52 EUR
1.1.5.2.1.33.SARAI120119T (3.2.1001.11-0032)Antibiootikumide doseerimine raskete infektsioonide korral01.01.201231.08.2015Joel StarkopfTartu Ülikool; Tartu Ülikool, Arstiteaduskond434 558,70 EUR
SFSF0182726s06HIV infektsioon Eestis: viiruse ja peremeesorganismi interaktsioonid molekulaarsel ja kliinilisel tasandil01.01.200631.12.2011Irja LutsarTartu Ülikool, Arstiteaduskond372 766,67 EUR
SFSF0180004s12Infektsioon immuunsüsteemi häirega isikutel - haiguse mehhanimidest kliinilise praktikani01.01.201231.12.2014Irja LutsarTartu Ülikool, Arstiteaduskond349 080,00 EUR
IUTIUT34-24Infektsioonid langenud immuunsusega isikutel – eksperimendist kliinilisse praktikasse01.01.201531.12.2020Irja LutsarTartu Ülikool, Meditsiiniteaduste valdkond, bio- ja siirdemeditsiini instituut698 400,00 EUR
ETFETF8799Meropeneemi farmakokineetika enneaegsetel vastsündinutel 01.01.201131.12.2012Irja LutsarTartu Ülikool, Arstiteaduskond35 388,00 EUR
SFSF0182587s03Müokardiinfarkti-järgne südamepuudulikkus : raskusastme determinandid, ravi ja prognoos01.01.200331.12.2006Rein TeesaluTartu Ülikool, Arstiteaduskond130 315,84 EUR
ETFETF6691Tiopuriinravimite farmakokineetikat ja -dünaamikat mõjutavad geneetilised ja mitte-geneetilised faktorid.01.01.200631.12.2007Kersti OselinTartu Ülikool, Arstiteaduskond14 847,96 EUR
SFSF0180059s07Uued ravistrateegiad neurodegeneratsiooni ja psüühiliste häirete ravis01.01.200731.12.2012Aleksandr ŽarkovskiTartu Ülikool, Arstiteaduskond791 857,51 EUR